Showing results (461-470 of 523) with videos related to
Sort By:
Pageof 53
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 17, 2022
S2k guideline: Diagnosis and treatment of chronic pruritusSonja Ständer, Claudia Zeidler, Matthias Augustin, et al.International Wound Journal|August 5, 2024
Assessing health-related quality of life using the Wound-QoL-17 and the Wound-QoL-14-Results of the cross-sectional European HAQOL study using item response theoryToni Maria Janke, Vlastimil Kozon, Skaidra Valiukeviciene, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 2, 2017
S2k Guidelines for the diagnosis and treatment of chronic pruritus - update - short versionSonja Ständer, Claudia Zeidler, Matthias Augustin, et al.Dermatology and Therapy|December 9, 2022
Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European InitiativeJan Koren, Jo L W Lambert, Simon F Thomsen, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 22, 2026
The worldwide burden of skin diseases: Lessons from the Global Burden of Disease dataLuigi Naldi, Simone Cazzaniga, Carsten Flohr, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 8, 2025
The SWITCH algorithm: An expert consensus on treat-to-target criteria for chronic prurigoLea S Stahl, Claudia Zeidler, Joyce Loewenthal, et al.Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.Archives of Dermatological Research|March 18, 2019
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective studyIrina Gasslitter, Natalia Kirsten, Matthias Augustin, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.Medicine|November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyKatharina C Kaehler, Christine Blome, Andrea Forschner, et al.Pageof 53